The Eastern Cooperative Oncology Group conducted a study of pentostatin (2'-deoxycoformycin) in 37 patients with hairy-cell leukemia. Among the 27 patients who met all the study's entry criteria, the response rate was 96 percent, with 16 patients (59 percent) entering complete remission and 10 patients (37 percent) partial remission. In one patient no response was observed. These results were not significantly changed by the inclusion of nine additional patients who were found retrospectively not to have fulfilled the entry criteria. When complete remission was attained, maintenance therapy was not given. Despite this, no patient has had a relapse, and the duration of complete remission ranges from 1 to 375 days. Pentostatin appears to be equally effective in untreated patients and in those who have progressive disease after splenectomy or after both splenectomy and treatment with interferon. Whether pentostatin is superior to splenectomy or interferon as therapy for hairy-cell leukemia will have to be assessed by direct comparison in randomized studies. Lengthy follow-up will be required to determine a median duration for the responses of hairy-cell leukemia to pentostatin.
This article has been cited by other articles:
Golomb, H. M.
(2008). Hairy Cell Leukemia: Treatment Successes in the Past 25 Years. JCO
26: 2607-2609
[Full Text]
Lamanna, N., Kalaycio, M., Maslak, P., Jurcic, J. G., Heaney, M., Brentjens, R., Zelenetz, A. D., Horgan, D., Gencarelli, A., Panageas, K. S., Scheinberg, D. A., Weiss, M. A.
(2006). Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. JCO
24: 1575-1581
[Abstract][Full Text]
Thomas, D. A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M. J., Giles, F. J., Cortes, J., Kantarjian, H. M.
(2003). Rituximab in relapsed or refractory hairy cell leukemia. Blood
102: 3906-3911
[Abstract][Full Text]
Weiss, M. A., Maslak, P. G., Jurcic, J. G., Scheinberg, D. A., Aliff, T. B., Lamanna, N., Frankel, S. R., Kossman, S. E., Horgan, D.
(2003). Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia. JCO
21: 1278-1284
[Abstract][Full Text]
von Rohr, A., Schmitz, S.-F. H., Tichelli, A., Hess, U., Piguet, D., Wernli, M., Frickhofen, N., Konwalinka, G., Zulian, G., Ghielmini, M., Rufener, B., Racine, C., Fey, M. F., Cerny, T., Betticher, D., Tobler, A.
(2002). Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol
13: 1641-1649
[Abstract][Full Text]
Federico, M., Zinzani, P. L., Frassoldati, A., Vinceti, M., Mode, A., Annino, L., Chisesi, T., Pagnucco, G., Invernizzi, R., Spriano, M., Resegotti, L., Bendandi, M., Damasio, E. E.
(2002). Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. JCO
20: 638-646
[Abstract][Full Text]
Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I.
(2001). Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. NEJM
345: 241-247
[Abstract][Full Text]
Kurzrock, R., Pilat, S., Duvic, M.
(1999). Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations. JCO
17: 3117-3121
[Abstract][Full Text]
Lauria, F., Bocchia, M., Marotta, G., Raspadori, D., Zinzani, P., Rondelli, D.
(1997). Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications. Blood
89: 1838-1839
[Full Text]
Kolesar, J. M., Morris, A. K., Kuhn, J. G.
(1996). Purine nucleoside analogues: fludarabine, pentostatin, and cladribine: Part 2: Pentostatin. J Oncol Pharm Pract
2: 211-224
[Abstract]
Fidias, P., Chabner, B. A., Grossbard, M. L.
(1996). Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders. The Oncologist
1: 125-139
[Abstract][Full Text]
Saven, A., Piro, L.
(1994). Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia. NEJM
330: 691-697
[Full Text]
